LivaNova (LIVN)
| Bid | 36.99 |
| Market Cap | 2.01B |
| Revenue (ttm) | 1.25B |
| Net Income (ttm) | 63.23M |
| EPS (ttm) | 1.16 |
| PE Ratio (ttm) | 31.91 |
| Forward PE | 9.5 |
| Analyst | Buy |
| Ask | 37.03 |
| Volume | 473,110 |
| Avg. Volume (20D) | 726,878 |
| Open | 37.00 |
| Previous Close | 37.00 |
| Day's Range | 36.34 - 37.08 |
| 52-Week Range | 32.48 - 64.47 |
| Beta | 0.90 |
About LIVN
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The ...
Analyst Forecast
According to 6 analyst ratings, the average rating for LIVN stock is "Buy." The 12-month stock price forecast is $60, which is an increase of 62.12% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · businesswire.com
LivaNova to Present at the Barclays Global Healthcare ConferenceLONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the ...